We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Portable Tool Can Diagnose and Monitor Sickle Cell Disease

By LabMedica International staff writers
Posted on 23 Jun 2023

Sickle cell disease is a lifelong, inherited blood disorder characterized by rigid, sickle-shaped red blood cells due to a severe alteration in their morphology. More...

These misshaped cells can clog blood vessels, impeding blood flow and leading to unpredictable, painful episodes when tissues become oxygen-deprived. The most prevalent and serious complications of sickle cell disease include anemia, pain, and organ failure – with stroke affecting roughly 10 out of every 100 children diagnosed with the condition. The primary objective in managing sickle cell disease is to prevent these painful crises, which require diagnostic and monitoring tools under medical supervision. However, current tools are cumbersome, expensive, and require specialized training. The gold standard methods used to monitor and diagnose the disease, primarily genetic tests and optical microscopy of sickle-shaped red blood cells, are time-consuming, prone to delays, and fail to capture real-time changes.

Currently, there are no commercial tools that allow for the continuous monitoring of sickle cell disease and no portable field sensor that can quantitatively measure and monitor cell sickling events using small blood samples. This leaves patients, whether diagnosed or undiagnosed, vulnerable. As morphological changes from repeated cell sickling events can result in permanent cell damage, rapid diagnosis, and treatment are critical. In response to this challenge, researchers at Florida Atlantic University (Boca Raton, FL, USA) have utilized microfluidics, flow cytometry, and electrical impedance to develop an innovative solution that offers patients a better means of managing their disease. Cytometry measures cells and other biological particles, while flow cytometry measures the size, shape, and quantity of cells moving in a fluid stream. Impedance-based flow cytometry provides information on individual particles by measuring changes in impedance values created by particles passing through measurement electrodes. Yet, the current equipment used for these measurements is expensive and cumbersome.

This new invention offers an alternative for patients and healthcare providers. The device consistently and swiftly monitors sickle cell disease using a microfluidics-based electrical impedance sensor, which can determine the rate of cell sickling and the percentage of sickled cells. It can identify the dynamic processes of cell sickling and unsickling in sickle blood without the need for microscopic imaging or biochemical markers. Assisted by a computer application created for the device, users can conduct impedance scans over specific time lengths, plot the measured impedance magnitude and phase, and directly share the raw data from a smartphone. This portable device, weighing approximately one pound, is handheld and simple to operate.

“There are many advantages to using this device such as portability and affordability,” said Sarah Du, Ph.D., an associate professor in Florida Atlantic University’s Department of Ocean and Mechanical Engineering within the College of Engineering and Computer Science, who recently received a patent from the United States Patent and Trademark Office for the novel invention. “Importantly, this device will provide users with measurements to diagnose their sickle cell disease severity and compare normal versus diseased sickle cell red blood cell samples. These longitudinal measurements will only require an extremely low sample of blood such as from a finger stick to allow patients to monitor their disease.”

“The combination of electrical impedance measurements and microfluidics provides a promising method to rapidly assess the dynamic processes of cell sickling and unsickling in patients with sickle cell disease," added Stella Batalama, Ph.D., dean, FAU College of Engineering and Computer Science. “Professor Du’s cutting-edge technology, which has received an important U.S. patent, will provide patients with sickle cell disease opportunities to reliably and conveniently monitor their disease in the same way patients with diabetes can monitor their disease using a glucometer.”

Related Links:
Florida Atlantic University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.